The Risk Of Developing ‘Long COVID’ Has Been Exaggerated, Say Researchers
September 29, 2023
Chinese Lab Suspected of COVID-19 Leak Stripped of United States Funding for Violating Biosafety Rules
October 5, 2023

Use of Antiviral Drug May be Fueling Evolution of COVID-19

News

Molnupiravir, an antiviral drug used to treat patients with COVID-19, may be causing mutations in the virus and fueling the evolution of new variants, scientists say.
[Source: theguardian.com]

Comment

Molnupiravir isn’t alone in fueling the evolution of COVID-19. Right from the start of the pandemic vaccination campaigns, many people were concerned that the widespread use of vaccines could encourage the coronavirus to evolve in ways that enable it to evade immunity.

The late Nobel prize-winning scientist Professor Luc Montagnier was in no doubt about this, asserting that history will show Covid vaccinations created viral variants. Predictably, of course, along with most of the mainstream media, the pharmaceutical and medical establishment remains in deep denial over this possibility. But with the Wall Street Journal having now examined the evidence and openly asked whether the vaccines are fueling new Covid variants, there are clear signs that the facts are beginning to emerge.

Growing evidence suggests that repeated vaccinations may be driving the rapid evolution of the coronavirus and making people more susceptible to new viral variants. The mutations of these variants enable them to evade antibodies resulting from previous Covid infections and vaccines, as well as existing monoclonal antibody treatments.

This evolutionary development of the coronavirus is essentially consistent with Darwinian theory and its description of the mechanisms of natural selection. Under selective evolutionary pressures, mutations that enable the virus to evade common antibodies have a better chance of surviving, reproducing, and transmitting.

To learn more about the possibility that new COVID-19 variants are being driven by vaccines, see this article on our website.